Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation

Chembiochem. 2024 Feb 16;25(4):e202300685. doi: 10.1002/cbic.202300685. Epub 2024 Jan 15.

Abstract

Thalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4CRBN to degrade its non-natural substrates may lead to undesired off-target effects for the IMiD-based PROTAC degraders. Herein, we reported a small library of potent and cell-permeable CRBN ligands, which exert high selectivity over the well-known CRBN neo-substrates of IMiDs by structure-based design. They were further utilized to construct bromodomain-containing protein 4 (BRD4) degraders, which successfully depleted BRD4 in the tested cells. Overall, we reported a series of functionalized CRBN recruiters that circumvent the promiscuity from traditional IMiDs, and this study is informative to the development of selective CRBN-recruiting PROTACs for many other therapeutic targets.

Keywords: CRBN; IMiDs; PROTAC; Targeted Protein Degradation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzimidazoles
  • Immunomodulating Agents
  • Ligands
  • Nuclear Proteins* / metabolism
  • Peptide Hydrolases* / metabolism
  • Phthalimides*
  • Proteolysis
  • Transcription Factors / metabolism
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • phthalimidine
  • Peptide Hydrolases
  • Nuclear Proteins
  • Transcription Factors
  • Ubiquitin-Protein Ligases
  • Immunomodulating Agents
  • Benzimidazoles
  • Ligands
  • Phthalimides